H.C. Wainwright raised the firm’s price target on BioNTech (BNTX) to $140 from $136 and keeps a Buy rating on the shares. The firm updated the company’s model post the Q3 report to reflect lower operating expenses.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX: